Liver transplantation in HIV-infected recipients

Seminars in Liver Disease

Volumn 26, Issue 3, 2006, Pages 273-284

  Roland, Michelle E ^a,b   Stock, Peter G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

End stage liver disease; Hepatitis; Human immunodeficiency virus; Transplantation

Indexed keywords

ABACAVIR; ADEFOVIR; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIMITOTIC AGENT; ANTIRETROVIRUS AGENT; ATOVAQUONE; CALCINEURIN INHIBITOR; CYCLOSPORIN; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENTECAVIR; GROWTH FACTOR; HEPATITIS B ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; PREDNISONE; PROTEINASE INHIBITOR; RAPAMYCIN; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TACROLIMUS; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; DRUG EFFECT; DYING; EVALUATION; FATTY LIVER; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; NONHUMAN; PATIENT SELECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TREATMENT INDICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; DISEASE MANAGEMENT; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; PATIENT SELECTION;

EID: 33746477548     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-947297     Document Type: Review

References (107)

1. Puoti M, Spinetti A, Ghezzi A, et al. Mortality from liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000;24:211-217
2. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001;17:1467-1471
3. Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004;18:2285-2293
4. Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003;17:1803-1809
5. Mocroft A, Soriano V, Rockstroh J, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005;19:2117-2125
6. Ragni MV, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005;11:1425-1430
7. Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr 2005;40:609-616
8. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497
9. Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 2001;32:1207-1214
10. Jain MK, Skiest DJ, Cloud JW, Jain CL, Burns D, Berggren RE. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin Infect Dis 2003;36:1030-1038
11. Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis 2002;186:1023-1027
12. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001;33:240-247
13. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362:1708-1713
14. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001;183:1112-1115
15. Thio CL, Seaberg EC, Skolasky RJr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-1926
16. Stock PG. Rapid deterioration of HIV co-infected patients waiting for liver transplantation is not predicted by MELD. Liver Transpl 2005;11:1315-1317
17. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta VA. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival [comments]. Clin Infect Dis 1999;29:150-154
18. Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999;15:1-4
19. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators [comments]. N Engl J Med 1998;338:853-860
20. Feinberg MB. Changing the natural history of HIV disease. Lancet 1996;348:239-246
21. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30(suppl 1):S5-S14
22. Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002;347:284-287
23. Roland ME, Havlir DV. Responding to organ failure in HIV-infected patients. N Engl J Med 2003;348:2279-2281
24. Roland ME, Lo B, Braff J, Stock PG. Key clinical, ethical, and policy issues in the evaluation of the safety and effectiveness of solid organ transplantation in HIV-infected patients. Arch Intern Med 2003;163:1773-1778
25. Thomas DL, Cannon RO, Shapiro CN, Hook EW III, Alter MJ, Quinn TC. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis 1994;169:990-995
26. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV-infected patients: prevalence and prognostic value. J Hepatol 1997;27:18-24
27. Newell A, Nelson M. Infectious hepatitis in HIV-seropositive patients. Int J STD AIDS 1998;9:63-69
28. Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis 1996;23:1117-1125
29. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis [comments]. J Hepatol 1997;26:1-5
30. Wright TL, Hollander H, Pu X, et al. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology 1994;20:1152-1155
31. Sanchez-Quijano A, Andreu J, Gavilan F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995;14:949-953
32. Piroth L, Duong M, Quantin C, et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998;12:381-388
33. Zylberberg H, Pialoux G, Carnot F, Landau A, Brechot C, Pol S. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 1998;27:1255-1258
34. Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy [letter]. AIDS 1998;12:116-117
35. Saves M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe Epidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS 1999;13:F115-F121
36. Puoti M, Gargiulo F, Roldan EQ, et al. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment. J Infect Dis 2000;181:2033-2036
37. Carr A, Morey A, Mallon P, Williams D, Thorburn DR. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 2001;357:1412-1414
38. Chariot P, Drogou I, de Lacroix-Szmania I, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999;30:156-160
39. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-1268
40. McCaughan GW, Spencer J, Koorey D, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999;5:512-519
41. Thorne C, Newell ML. The safety of antiretroviral drugs in pregnancy. Expert Opin Drug Saf 2005;4:323-335
42. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003;34(suppl 1):S21-S33
43. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Panel on clinical practices for treatment of HIV infection convened by the Department of Health and Human Services (DHHS). October 6, 2005
44. Sheppard HW, Ascher MS. The natural history and pathogenesis of HIV infection. Annu Rev Microbiol 1992;46:533-564
45. Molossi S, Clausell N, Sett S, Rabinovitch M. ICAM-1 and VCAM-1 expression in accelerated cardiac allograft arteriopathy and myocardial rejection are influenced differently by cyclosporine A and tumour necrosis factor-alpha blockade. J Pathol 1995;176:175-182
46. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC. Activation-induced death by apoptosis in CD4 + T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992;175:331-340
47. Andrieu JM, Even P, Venet A, et al. Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease. Clin Immunol Immunopathol 1988;47:181-198
48. Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, Bieniasz PD. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med 2003;9:1138-1143
49. Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002;109:681-688
50. Rizzardi GP, Lazzarin A, Pantaleo G. Potential role of immune modulation in the effective long-term control of HIV-1 infection. J Biol Regul Homeost Agents 2002;16:83-90
51. Martin LN, Murphey-Corb M, Mack P, et al. Cyclosporin A modulation of early virologic and immunologic events during primary simian immunodeficiency virus infection in rhesus monkeys. J Infect Dis 1997;176:374-383
52. Chapuis AG, Paolo Rizzardi G, D'Agostino C, et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000;6:762-768
53. Margolis D, Hossain M, Shaw L, Back D. The addition of mycophenolate mofetil can induce decreases in HIV-1 RNA and intracellular deoxyguanosine triphosphate (Abstract presented at the 5th International Workshop on HIV-1 Drug Resistance, Scottsdale, AZ). Antivir Ther 2001;6(suppl 1):11
54. Hossain MM, Coull JJ, Drusano GL, Margolis DM. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res 2002;55:41-52
55. Garcia F, Plana M, Arnedo M, et al. Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study. J Acquir Immune Defic Syndr 2004;36:823-830
56. Calabrese LH, Lederman MM, Spritzler J, et al. Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation. J Acquir Immune Defic Syndr 2002;29:356-362
57. Margolis D, Heredia A, Gaywee J, Oldach D, Drusano G, Redfield R. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999;21:362-370
58. Heredia A, Amoroso A, Davis C, et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress RS strains of HIV-1. Proc Natl Acad Sci USA 2003;100:10411-10416
59. Heredia A, Margolis D, Oldach D, Hazen R, Le N, Redfield R. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. J Acquir Immune Defic Syndr 1999;22:406-407
60. Schwarz A, Offermann G, Keller F, et al. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation: data on four cases and review of the literature. Transplantation 1993;55:95-103
61. Margolis DM, Kewn S, Coull JJ, et al. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2002;31:45-49
62. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317-1323
63. Dummer JS, Erb S, Breinig MK, et al. Infection with human immunodeficiency virus in the Pittsburgh transplant population: a study of 583 donors and 1043 recipients, 1981-1986. Transplantation 1989;47:134-140
64. Poli F, Scalamogna M, Pizzi C, Mozzi F, Sirchia G. HIV infection in cadaveric renal allograft recipients in the North Italy Transplant Program. Transplantation 1989;47:724-725
65. Tzakis AG, Cooper MH, Dummer JS, Ragni M, Ward JW, Starzl TE. Transplantation in HIV + patients. Transplantation 1990;49:354-358
66. Erice A, Rhame FS, Heussner RC, Dunn DL, Balfour HH Jr. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. Rev Infect Dis 1991;13:537-547
67. Bouscarat F, Samuel D, Simon F, Debat P, Bismuth H, Saimot AG. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1. Clin Infect Dis 1994;19:854-859
68. Ahuja TS, Zingman B, Glicklich D. Long-term survival in an HIV-infected renal transplant recipient. Am J Nephrol 1997;17:480-482
69. Ragni MV, Bontempo FA, Lewis JH. Organ transplantation in HIV-positive patients with hemophilia [letter; comments]. N Engl J Med 1990;322:1886-1887
70. Stock PG, Roland ME, Carlson L, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003;76:370-375
71. Roland ME, Adey D, Carlson LL, Terrault NA. Kidney and liver transplantation in HIV-infected patients: case presentations and review. AIDS Patient Care STDS 2003;17:501-507
72. Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003;75:425-429
73. Roland MCL, Terrault N, Preise C, Hirose R, Rogers R, Stock P. Patient and graft outcomes following solid organ transplantation. Paper presented at: 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, CA
74. Neff GW, Bonham A, Tzakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003;9:239-247
75. Prachalias AA, Pozniak A, Taylor C, et al. Liver transplantation in adults coinfected with HIV. Transplantation 2001;72:1684-1688
76. Norris S, Taylor C, Muiesan P, et al. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 2004;10:1271-1278
77. Moreno S, Fortun J, Quereda C, et al. Liver transplantation in HIV-infected recipients. Liver Transpl 2005;11:76-81
78. Rafecas A, Rufi G, Figueras J, et al. Liver transplantation without steroid induction in HIV-infected patients. Liver Transpl 2004;10:1320-1323
79. Vogel M, Voigt E, Schafer N, et al. Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: outcome of 7 patients from the Bonn cohort. Liver Transpl 2005;11:1515-1521
80. Radecke K, Fruhauf NR, Miller M, et al. Outcome after orthotopic liver transplantation in five HIV-infected patients with virus hepatitis-induced cirrhosis. Liver Int 2005;25:101-108
81. Honkoop P, Kazemier G, Perenboom RM, van de Ende ME, de Man RA. [Liver transplantation in a HIV-positive patient receiving potent antiretroviral therapy: the first case in The Netherlands]. Ned Tijdschr Geneeskd 2004;148:2500-2504
82. Polard E, Camus C, Abault AY, et al. Retransplantation for acute liver failure due to combined antiviral agents in an HIV-HCV coinfected liver transplant recipient. Transplantation 2005;80:1136-1138
83. Antoniades C, Macdonald C, Knisely A, Taylor C, Norris S. Mitochondrial toxicity associated with HAART following liver transplantation in an HIV-infected recipient. Liver Transpl 2004;10:699-702
84. Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000;31:162-166
85. Tien PC, Grunfeld C. The fatty liver in AIDS. Semin Gastrointest Dis 2002;13:47-54
86. Moreno A, Quereda C, Moreno L, et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther 2004;9:133-138
87. Moreno A, Quereda C, Barcena R. Successful pregnancy after orthotopic liver transplantation in a patient with HIV infection. N Engl J Med 2005;353:2517-2518
88. Jain A, Venkataramanan R, Shapiro R, et al. The interaction between anti-retroviral agents and tacrolimus in liver and kidney transplant patients. Paper presented at: American Transplant Congress, 2002; Washington, DC
89. Guaraldi G, Cocchi S, Codeluppi M, et al. Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation. Transplant Proc 2005;37:2609-2610
90. Frassetto L, Baluom M, Jacobsen W, et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005;80:13-17
91. Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004;10:939-944
92. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-723
93. Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000;7:161-165
94. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000;30(suppl 1):S77-S84
95. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-1306
96. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-1310
97. Thibault V, Benhamou Y, Seguret C, et al. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol 1999;37:3013-3016
98. Terrault NA, Carter JT, Carlson L, Roland ME, Stock PG. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 2006;12:801-807
99. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;2:696-699
100. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Recomm Rep 1999;48:1-59, 61-56
101. Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 2001;93:843-849
102. Palefsky JM, Holly EA, Ralston ML, et al. Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papilloma-virus infection. J Acquir Immune Defic Syndr 2001;28:422-428
103. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002;35:1127-1134
104. Roland ME, Stock PG. Comprehensive guidelines translate research findings into clinical policy for HIV-infected transplant candidates and recipients. Enferm Infecc Microbiol Clin 2005;23:331-334
105. Tien PC. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J Gastroenterol 2005;100:2338-2354
106. Miro JM, Moreno A, Tuset M, et al, and the HIV SOT Working Group. GESIDA/GESITRA-SEIMC, SPNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patient in Spain. 2005
107. O'Grady J, Taylor C, Brook G. Guidelines for liver transplantation in patients with HIV infection (2005). HIV Med 2005;6(suppl 2):149-153